ALKS.V Stock Overview
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Alkermes plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.64 |
| 52 Week High | US$25.55 |
| 52 Week Low | US$22.49 |
| Beta | 0.62 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALKS.V | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | 1.5% | 1.2% |
| 1Y | n/a | 1.1% | 24.7% |
Return vs Industry: Insufficient data to determine how ALKS.V performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ALKS.V performed against the US Market.
Price Volatility
| ALKS.V volatility | |
|---|---|
| ALKS.V Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALKS.V has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALKS.V's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 2,280 | Richard Pops | www.alkermes.com |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells.
Alkermes plc Fundamentals Summary
| ALKS.V fundamental statistics | |
|---|---|
| Market cap | US$3.90b |
| Earnings (TTM) | US$214.72m |
| Revenue (TTM) | US$1.59b |
18.2x
P/E Ratio2.5x
P/S RatioIs ALKS.V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKS.V income statement (TTM) | |
|---|---|
| Revenue | US$1.59b |
| Cost of Revenue | US$236.91m |
| Gross Profit | US$1.35b |
| Other Expenses | US$1.14b |
| Earnings | US$214.72m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.29 |
| Gross Margin | 85.11% |
| Net Profit Margin | 13.50% |
| Debt/Equity Ratio | 21.5% |
How did ALKS.V perform over the long term?
See historical performance and comparison